SEC For	rm 4 FORM	4 U			TES :	SEC					XCHAN	IGE (COM	MIS	SIO	N			
Washington, D.C. 20549																	OMB APPROVAL		
to Section 16. Form 4 or Form 5 obligations may continue. See						IT OF CHANGES IN BENEFICIAL OWN pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											Estimated average burden		3235-0287 en 0.5
1. Name and Address of Reporting Person [*] Cahill Brian Joseph					<u>EA</u>	2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]									all app Direct	licable)	10% O		wner
(Last)(First)(Middle)C/O EAGLE PHARMACEUTICALS, INC.50 TICE BOULEVARD, SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 02/02/2022								A below) below) Chief Financial Officer					
(Street) WOODCLIFF LAKE NJ 07677				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 						
(City) (State) (Zip)																			
		Table	I - No	n-Deriva	tive S	Secu	rities	s Acc	uired,	, Dis	posed of	, or Be	nefic	ally	Own	ed			
1. Title of Security (Instr. 3) Date (Month/Da					Execution Date,			3.4. SecuritieTransactionDisposed 0Code (Instr.5)8)					and Securitie Beneficia		ies cially Following	Forn (D) o	n: Direct	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Pric	e	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 02/02/2					022			F ⁽¹⁾		805	D	\$45	5.03	24,667			D		
		Tal	ble II -								osed of, convertib				Owneo	k			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any	any Ionth/Day/Year)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)		vative nrities nired r osed) r. 3, 4	Expiration Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4) Amoun or Number of Title Shares		Deri Sec (Ins	rice of vative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld to satisfy withholding tax obligations.

Remarks:

/s/ Brian Cahill

02/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.